Baseline characteristics of FINRISK 2002 discovery cohort (n=6548) and FHS Offspring (n=2886) and DILGOM 2007 (n=3905) replication cohorts
| FINRISK 2002 | Replication cohort (FHS) | Replication cohort (DILGOM) | ||||
| Women n=3423 | Men n=3125 | Women n=1571 | Men n=1315 | Women n=2059 | Men n=1846 | |
| Age, years | 45.6 (20.8) | 46.6 (19.9) | 66.4 (9.0) | 66.3 (9.0) | 49.8 (13.4) | 50.7 (13.1) |
| Weight, kg | 69.5 (16.6) | 84.5 (17.3) | 71.5 (15.8) | 88.5 (15.9) | 70.7 (13.9) | 84.7 (13.9) |
| Height, m | 1.63 (0.08) | 1.76 (0.09) | 1.61 (0.06) | 1.75 (0.07) | 1.63 (0.06) | 1.76 (0.07) |
| BMI, kg/m2 | 26.3 (6.2) | 27.2 (5.1) | 27.7 (5.9) | 29.0 (4.7) | 26.7 (5.3) | 27.3 (4.1) |
| Waist-to-hip ratio | 0.84 (0.08) | 0.96 (0.09) | 0.86 (0.06) | 0.97 (0.07) | ||
| Mean systolic blood pressure, mm Hg | 131 (26) | 136 (22) | 128 (18) | 129 (17) | 133 (21) | 138 (19) |
| HbA1c, mmol/mol | 36.2 (5.0) n=1840 | 36.4 (5.0) n=1758 | ||||
| HDL, mmol/L* | 1.59 (0.53) | 1.30 (0.43) | 1.65 (0.47) | 1.28 (0.37) | 1.53 (0.49) | 1.27 (0.40) |
| LDL, mmol/L* | 3.07 (1.11) | 3.38 (1.20) | 2.84 (0.82) | 2.58 (0.78) | 3.04 (1.13) | 3.12 (1.16) |
| Triglycerides, mmol/L* | 1.07 (0.63) | 1.41 (1.01) | 1.31 (0.69) | 1.36 (0.88) | 1.08 (0.66) | 1.40 (0.98) |
| hs-CRP, mmol/L* | 1.15 (2.07) | 1.10 (1.66) | 1.17 (2.00) | 1.09 (1.63) | ||
| Current smokers, n (%) | 761 (22.3%) | 1006 (32.3%) | 147 (9.4%) | 111 (8.5%) | 307 (14.9%) | 411 (22.2%) |
| Education, n (%) | ||||||
| Low | 1132 (33.6%) | 1071 (34.8%) | 656 (31.9%) | 522 (28.3%) | ||
| Middle | 1105 (32.8%) | 1001 (32.5%) | 689 (33.5%) | 646 (35.0%) | ||
| High | 1131 (33.6%) | 1004 (32.6%) | 693 (33.7%) | 668 (36.2%) | ||
| Physical activity at leisure time, n (%) | ||||||
| Low level or no exercise | 777 (22.7%) | 718 (23.0%) | 374 (18.2%) | 345 (18.7%) | ||
| Light exercise, at least 4 hours per week | 1893 (55.3%) | 1585 (50.7%) | 1111 (54.0%) | 936 (50.7%) | ||
| Aerobic exercise, at least 3 hours per week, or regular exercise at competitive level | 753 (22.0%) | 822 (26.3%) | 574 (27.9%) | 565 (30.6%) | ||
| Use of antihypertensive medicines, n (%) | 428 (12.5%) | 376 (12.0%) | 699 (44.6%) | 701 (53.6%) | 357 (17.3%) | 341 (18.5%) |
| Use of lipid-lowering medication, n (%) | 220 (6.4%) | 224 (7.2%) | 229 (11.1%) | 298 (16.1%) | ||
| Prevalent CVD, n (%) | 48 (1.4%) | 126 (4.0%) | 38 (1.8%) | 94 (5.1%) | ||
| Family history of diabetes, n (%) | 897 (26.2%) | 731 (23.4%) | 629 (30.5%) | 474 (25.7%) | ||
| Prevalent T2DM, n (%) | 80 (2.3%) | 87 (2.8%) | 135 (8.6%) | 166 (12.6%) | 52 (2.5%) | 92 (4.9%) |
Means (IQRs) for continuous variables, frequencies (percentage) for categorical variables.
*Geometric means used due to skewed distribution.
BMI, body mass index; CVD, cardiovascular disease; DILGOM, DIetary, Lifestyle and Genetic determinants of Obesity and Metabolic syndrome; FHS, Framingham Heart Study; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C reactive protein; LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus.